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SUMMARY
A retrospective study analysed 359 proven or presume cases of loxoscelism seen at the Hospital Vital Brazil, Instituto Butantan,
São Paulo, Brazil, between 1985 and 1996. The spider was identified in 14%. The bites occurred predominantly in the urban areas
(73%) between September and February. Patients > 14 years were commonest inflicted (92%) and 41% were bitten while getting
dressed. Only 11% sought medical care within the first 12 hours post bite.
Cutaneous loxoscelism was the commonest form presenting (96%); commonest manifestations were: pain (76%), erythema
(72%), edema with enduration (66%), ecchymosis (39%). Skin necrosis occurred in 53% of patients, most frequently seen on trunk,
tigh and upper arm, and when patients seek medical care more than 72 hours after bite. Local infection was detected in 12 patients
(3%). Hemolysis was confirmed in 4 cases (1.1%). Generalised cutaneous rash, fever and headache were also observed in 48% of the
total of patients. None of them had acute renal failure or died. Treatment usually involved antivenom administration (66%), being
associated with corticosteroids (47%) or dapsone (30%). Presumptive diagnosis of loxoscelism may be established based on clinical
and epidemiological findings. Further investigations are required to prove the value of antivenom and other treatment schedules.
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INTRODUCTION
Loxosceles genus includes several different spider species and
represents an important cause of necrotic arachnidism. The brown spider
(vulgar name) may range in length from 1-5 cm leg to leg, fawn to dark
brown in color, and has on its dorsal cephalotorax a fiddle-shapped dark
brown marking. There is no evidence that the spider is aggressive; on
the contrary, the animal is retiring and prefers living in dark areas. The
spider has extended its habitat to include homes, garages, and barns,
where encounters with humans are more likely. In Brazil, three species
have been mostly implicated in human envenoming: L. gaucho, L. laeta
and L. intermedia17.
Necrotic and viscerocutaneous arachnidism in consequence of
Loxosceles spider bite (loxoscelism) has been reported in South
America6,18,26,27,28, North America2,11,15,24, Southern Africa19,20 and Israel5.
There are no reports of loxoscelism in Australia, but it is likely that
many cases of necrotic arachnidism would be caused by Loxosceles
spiders35. In Brazil, between 1990 and 1993, more than 6,500 human
accidents had been attributed to Loxosceles spp, corresponding to 37%
of poisonous spider bites in Brazil, most of cases registered in the South
region (95%), followed by the Southeast (4%)6. The loxoscelism is
particularly prominent in the metropolitan area of Curitiba, Paraná State,
which accounts for about 2,000 cases per year (unpublished data).
Loxoscelism is notorious for producing a necrotic skin ulcer that
heals slowly and may require surgical excision or skin grafting. Systemic
involvement (viscerocutaneous form) is much less common and is the
cause of the rare deaths, usually associated with acute renal failure and
disseminated intravascular coagulation due to intravascular hemolysis27,28.
The mechanisms involved in the pathophysiology of Loxosceles
envenoming are complex. Venom is rich in many enzymes such as
hydrolases, hyalurodinase, lipases, peptidases, collagenases, alkalin
phosphatase, 5-ribonucleotidase, phosphohydrolases, proteases13,15,22,23.
A key component for the dermonecrotic lesion appears to be
sphyngomyelinase D, that interacts with the cellular membrane, unchains
reactions involving components of the complement system, platelets,
and polymorphonuclear leukocytes15,29,33. Sphyngomyelinase D activity
was also proved to be responsible for the intravascular hemolysis14, which
is mediated by the complement system30,31, and secondary to activation
of endogenous metalloproteases32.
Diagnosis of loxoscelism is rarely based on the identification of the
spider. Unless the patient catches the animal and brings it in for formal
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identification, the diagnosis is only presumptive, based solely on clinical
signs and symptoms. In the early stages, cutaneous loxoscelism may be
misdiagnosed as cellulitis or an insect sting. Although incipient laboratory
tests have been perfomed8,9, no definitive immunodiagnosis is yet
available.
Most of published reports of Loxosceles spider bites are of individual
cases or of limited series. In contrast, our objective was to describe a
long term historical series of definite and presume loxoscelism, in order
to define clinical and epidemiological features that may be of fundamental
importance to the diagnosis.
PATIENTS AND METHODS
A retrospective study was made by reviewing the records of patients
with definite or presume loxoscelism who had been referred to the
Hospital Vital Brazil (HVB), Instituto Butantan, São Paulo, Brazil,
between January 1985 to December 1996. Instituto Butantan is a venom
research centre, has a antivenom production division, and a health service
specialized in the treatment of patients bitten by venomous animals. We
selected cases in which suggestive clinical manifestations of Loxosceles
envenoming were present, whether the spider was identified or not.
Epidemiological and clinical information, such as date of bite, type of
activity concurrently undertaken when patient was bitten, time elapsed
until presentation to hospital, location and appearance of lesion upon
admission, systemic effects, treatment administered and outcome, were
recorded. Cutaneous loxoscelism was defined as a combination of skin
puncture lesion, usually with an eccentric serous or hemorrhagic
blistering and ecchymosis, surrounded by an irregular pale area, that
could not be attributable to any other dermatological lesion, usually
present in the first 2-3 days after bite. In cases where patients were seen
later, the initial lesion might had evolved to an area of central necrosis,
with a sharply-defined ulceration rim and a base of granulation tissue.
Viscerocutaneous loxoscelism was defined when intravascular hemolysis
was suspected, irrespective of severity of the local reaction. If the agent
was brought by the patient or relatives, the identification of the specimen
had been made by a arachnologist and a definite diagnosis of loxoscelism
was made; otherwise, presume loxoscelism was considered. Heterologous
specific Loxosceles or polyvalent antivenom (for Loxosceles sp,
Phoneutria sp and Tityus sp) was given to those patients who had not
necrotic ulcer on admission. All antivenoms were (Fab’)2
immunoglobulins produced by Instituto Butantan and dispensed in 5 ml
vial, each ml neutralizing 15 minimal necrotizing dose of L. gaucho
venom. Antivenom was given intravenously and the amount varied
according to envenoming severity. Prednisone (40-60 mg/d for 5 to
7 days) and dapsone (100 mg/d for 7 days) were occasionally
administered in a tentative to reduce the inflammatory reaction.
Intravascular hemolysis was suspected when jaundice was present and
confirmed if one of the following laboratorial tests was altered:
hemoglobin (Hb) < 11.0/13.0 g/dL (female/male), packed cell volume
(PCV) < 37/40% (female/male), total bilirubin (TB) > 1.0 mg/dL, or
indirect bilirubin (IB) > 0.6 mg/dL.
A database of this pooled information was constructed and frequency
distribution of the variables were obtained using the Epi-Info 6.04
software. The chi-square test was used to compare proportions and
statistical significance was considered when p < 0.05.
RESULTS
Three hundred and fifty-nine records were analysed, with a mean of
30 cases per year. Most of the bites occurred in urban areas (73%), season
variation cases occurred predominantly between September and February,
which corresponds to Spring and Summer in Southern Brazil (Fig. 1).
No gender difference was observed: 52% out the patients were male and
48% were female (p = 0.49). The minority of bites (7%) occurred in
patients under 15 years old (mean age = 34.7 ± 15.4 years old; median =
34). The interval between the time of the bite and presentation to hospital
was usually more than 12 hours (90%), almost half of the patients sought
medical care 2 days after of the bite. The most affected anatomical areas
were thigh and trunk (Table 1), reflecting the circumstances of the bite
event. Most patients (93%) had a history of spider bite and accidents
occurred more frequently while dressing (42%) or sleeping (18%). The
causal spider was brought by 51 patients (14%), 28 being classified as
L. gaucho, 5 as L. laeta and 18 as Loxosceles sp (species unascertainable).
The predominant clinical features were related to cutaneous
loxoscelism (96.4%). On admission pain, erythema, oedema with
induration, and ecchymosis were frequently seen (Table 2). Necrotic
lesion that dropped off leaving an ulcer was observed in 191 patients
(53%), being 122 on admission, and 69 after antivenom therapy. Necrosis
was more frequently observed when the bite occurred in proximal
anatomic areas, such as trunk, thigh and upper arm (p = 0.0002) and in
those patients who arrived at the hospital 72 hours or more after the
accident (p < 0.0001). In the follow-up period, which varied from one to
eight weeks, mild local infection was detected in 12 patients (3%), and
healing with scar in 15 (4%).
Viscerocutaneous loxoscelism was suspected in 13 patients that
presented jaundice on admission or in the subsequent days after
hospitalization. Of these, laboratory tests showed decrease of
hematological parameters in 4 cases (Table 3). In one case, data was not
available since patient was transferred to the referral hospital. Agent
was not brought for identification in none of the viscerocutaneous cases
therefore relation between severity and Loxosceles species was not
established. Unspecific symptoms were evident in 172 patients (48%),
either cutaneous or viscerocutaneous loxoscelism, but were commoner
in the latter form. Itching morbilliform or scarlatiniform skin eruption
Fig. 1 - Monthly distribution of loxoscelism. Hospital Vital Brazil (HVB), Instituto Butantan,
1985-1996.
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Table 3
Viscerocutaneous loxoscelism in 12 patients. Hospital Vital Brazil, 1985-1996
No. Age (years) Sex Interval between bite and jaundice Hb/PCV* Total bilirubin / indirect bilirubin
1 3 M  16 h 5.0 / 10 -
2 33 M 3 days 15.5 / 43 2.9 / 2.5
3 16 F 2 days 7.9 / 21 3.2 / 2.9
4 41 M  2 days - / - 2.4 / 1.9
5 17 F 10 days 6.1 / 19 - / -
6 29 M 5 days 13.6 / 37 2.0 / 1.3
7 37 F 13 days 12.4 / 37 3.9 / 1.8
8 42 F  3 days 13.6 / 40 2.6 / 1.7
9 22 M 2 days - / - 3.7 / 3.0
10  46 F 7 days - / - 3.5 / 2.4
11 33 F 2 days 4.4 / - 2.1 / 1.6
12 15 M 2 days - / - 3.7 / 3.0
* Hb: hemoglobin; PCV: packed cell volume; 1 record not available
Table 1
Epidemiological features of loxoscelism in 359 patients. Hospital Vital Brazil,
1985-1996
Age (years) N %
Under 15 25 7
15-29 120 33
30-44 122 34
45-59 68 19
60 or more 21 6
Unknown 3 1
Interval between accident and presentation to hospital N %
< 12 hours 38 10
12-24 hours 83 23
1-2 days 65 18
2-3 days 53 15
3-4 days 39 11
 4 days 81 23
Site of bite N %
Trunk 56 16
Upper arm 54 15
Thigh 124 34
Other 124 34
Not recorded 1 0
Table 2
Local signs and symptoms of loxoscelism in 359 patients on admission at
Hospital Vital Brazil, 1985-1996
Local symptomatology Frequency %
Pain 274 76
Erythema 259 72
Edema + induration 236 66
Ecchymosis 139 39
Necrosis 122 34
Blister 51 14
was observed in 32%, low grade fever (37.5 – 38.5 ºC) in 16% and
headache in 10% of the total number of patients, which disappeared in
the first three days.
Regarding to the treatment schedules, 237 patients (66%) received 5
to 75 ml of specific antivenom (mean = 28 ± 13.5 ml); of these, antivenom
was combined with corticosteroid in 47%, and with dapsone in 30%.
Early anaphylactic reactions, mostly mild (urticaria and nausea) and not
life threating, were observed in 20%. No acute renal failure, disseminated
intravascular coagulation or death were registered.
DISCUSSION
Loxosceles spider bite is a well-documented cause of dermonecrotic
lesion in humans. This study describes a retrospective analysis of a large
series of loxoscelism from São Paulo metropolitan area (São Paulo State,
Brazil). We conclude that loxoscelism could be even more common that
we observed due to the absence of a specific diagnostic test and the fact
of the spider is not usually captured and identified.
Many of the characteristics presented herein are similar to those
reported elsewhere for patients bitten by Loxosceles spiders: most patients
fell within age range from 15 to 59 years, were equally distributed by
gender, most bites occurred during warm seasons, and the most frequent
site of bite was the thigh and trunk27,28. Interestingly, 93% could give a
history of spider bite, in contrast with other authors’ observations7,34 that
referred that most accidents go unnoticed until the appearance of a local
lesion. Of the 51 spiders that had been brought and identified, the most
prevalent species was L. gaucho. Other studies in Brazil and elsewhere
implicate a variety of species, such as L. intermedia25, L. laeta27,28,37, L.
reclusa24, and L. rufescens5,34. Experimentally, different Loxosceles
venoms are associated with varying degrees of toxicity3,35 and may reflect
differences in clinical presentation and severity of envenoming.
The diagnosis of loxoscelism is rarely based on absolute identification
on the spider and patients are usually bitten while sleeping or dressing.
Usually a specimen of Loxosceles is found in the bedclothes adjacent to
the bite area on awakening from sleep. Since the bite is relatively painless,
some patients may even be not aware that a spider bite has occurred and
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fang marks are seldom visible. There is frequently a transitory stinging
at the time of the bite and mild or severe reaction begins after some
hours. One of the difficulties making the correct diagnosis is the fact
that, in early stages, the lesion does not present clearly defined aspects
but may be mistaken for cellulitis or insect bites.
The local reaction of the brown spider bite described here varied
considerably, from mild pain and erythema to extensive skin necrosis
with ulceration. In most of our cases, diagnosis was made in the presence
of painful edema with enduration and ecchymosis, surrounded by a livid
area, that progressed slowly, associated with a history of spider bite. In
those with a large and deep necrosis, ulceration lasted several months
before healing. Even in the presence of necrotic lesion, local infection
was not so common; all were treated with oral antibiotics, and had no
systemic complications. Besides the cutaneous lesion, unspecific
manifestations, such as fever, headache, and a generalized, pruritic,
morbilliform or scarlatiniform rash may occur in the first 24 to 48 hours
post bite. Although not present in all of our patients, the presence of
these unspecific clinical features assisted in making the diagnosis of
loxoscelism.
Viscerocutaneous loxoscelism is relatively uncommon and may have
a course independent of the local reaction. The frequency of this form
observed in our study was lower than has been reported by other
authors27,28. Some spider factors are speculated to be associated with
poorer bite outcome, such as sex21, ontogenetic variations1 and species28.
In Santa Catarina State, Brazil, where L. laeta is frequently found,
hemolysis was described in 13%28; a similar proportion of viscero-
cutaneous form were found in Chile, where L. laeta is also a prevalent
species27. Certain characteristics of the patient, such as age15 and genetic
variations4 may also be implicated in the severity of envenomation. In
some of our patients, jaundice was observed more than one week after
bite, which highlights for the possibility of late hemolysis, not impaired
by antivenom. This fact contrast with other studies in which hemolytic
anemia was observed up to the third day after bite15,34,35, and suggests
the participation of endogenous mediators in the generation of systemic
alterations, as demonstrated experimentally32.
A great deal of controversy exists regarding the value of drugs and
antivenom in the treatment of loxoscelism23,36,37. In our study, 19% of
patients develop necrosis despite being treated with antivenom. Although
skin necrosis was therefore not prevented, we cannot conclude that
antivenom is totally inefficient to reduce the extend of dermatological
lesion. In this way, antivenom is routinely given, in our hospital, in
patients in which necrosis is still not present. The proportion of early
anaphylactic reactions was not exceptionally high and similar to that
observed for other antivenoms10,12, and manifestations were promptly
reversed by proper measures.
In parallel, drugs with anti-inflammatory activities, such as dapsone
and corticosteroids, have also been used in an attempt to reduce the
extension of necrosis. The efficacy of dapsone in the treatment of skin
diseases in which polymorphonuclear leucocytes play a prominent role
is the rationale for its using in Loxosceles spider bite. Apparently a mild
reduction of the cutaneous lesion was observed in patients that used
high doses of prednisone in a short term schedule. On the other hand,
dapsone seemed to not alter the progression of the dermonecrosis, which
contrasts with some reports of an apparent effectiveness of this drug in
reducing the extent of skin damage16,24. However, no controlled clinical
trials have been conducted and the best therapeutic schedule in the
treatment of loxoscelism is still to be defined. Furthermore, the
effectiveness of either treatment depends on the time between bite and
medical assistance.
In conclusion, loxoscelism produces a highly suggestive picture,
and the sum of clinical and epidemiological findings may establish the
diagnosis, even if the spider is not captured and identified.
RESUMO
Aspectos clínicos e epidemiológicos do loxoscelismo
em São Paulo, Brasil
Foram analisados, em um estudo retrospectivo, 359 casos de
loxoscelismo comprovados ou presumidos, acompanhados no Hospital
Vital Brazil, Instituto Butantan, São Paulo, Brasil, entre 1985 e 1996. A
aranha foi identificada em 14% dos casos. Os acidentes predominaram
nas áreas urbanas (73%), entre setembro e fevereiro. Pacientes maiores
de 14 anos foram mais freqüentemente atingidos (92%) e 41% foram
picados ao se vestir. Apenas 11% procuraram o serviço médico nas
primeiras horas após a picada.
A forma cutânea foi a mais freqüente (96%), sendo as principais
manifestações descritas: dor (76%), eritema (72%), edema com enduração
(66%), equimose (39%). Necrose cutânea ocorreu em 53% dos pacientes,
sendo mais freqüentemente observada no tronco, coxa e braço, e naqueles
que procuraram atendimento médico mais de 72 horas após o acidente.
Infecção local foi detectada em 12 pacientes (3%). A hemólise foi
confirmada em 4 casos (1,1%). Exantema generalizado, febre e cefaléia
foram observados em 48% dos pacientes. Não se verificou insuficiência
renal ou óbito. O antiveneno foi administrado em 66% dos casos,
associado a corticosteróide em 47% ou a dapsona em 30%. O diagnóstico
presuntivo de loxoscelismo pode ser estabelecido baseado em achados
clínicos e epidemiológicos. Maiores investigações são necessárias para
se comprovar o valor do antiveneno e outras drogas.
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